trial summary · NCT07851259
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase II, Randomized, Double-Masked, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of RO7965032 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Trial record from the TrialBase DB dataset, status RECRUITING, condition Geographic Atrophy Secondary to Age-Related Macular Degeneration, sponsored by Genentech, Inc.. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Source record: https://clinicaltrials.gov/study/NCT07851259
Facts
| registry id | NCT07851259 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Geographic Atrophy Secondary to Age-Related Macular Degeneration |
| sponsor | Genentech, Inc. |
| sponsor class | INDUSTRY |
| enrollment | 321 |
| start date | 2027-01-08 |
| primary completion | 2030-08-21 |
| completion | 2030-08-21 |
| results posted | not reported |
Conditions
- Geographic Atrophy Secondary to Age-Related Macular Degeneration
Interventions
- RO7965032
- Placebo
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.